The effective clinical use of EGFR inhibitors for oesophageal cancer patients has been hampered by a lack of optimal patient stratification in trials, imperfect predictive biomarkers, non-responders to treatment and the development of drug resistance in all patients who had initially derived benefit from treatment [43]. This evidence concerns the gene EGFR and carcinoma of esophagus.